Stifel Nicolaus Forecasts Strong Price Appreciation for Medexus Pharmaceuticals (TSE:MDP) Stock

Medexus Pharmaceuticals (TSE:MDP) had its target price hoisted by analysts at Stifel Nicolaus from C$4.15 to C$4.50 in a research note issued on Tuesday,BayStreet.CA reports. Stifel Nicolaus’ price objective points to a potential upside of 3.93% from the stock’s current price.

Several other research firms also recently commented on MDP. Raymond James upgraded shares of Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 price target for the company in a research note on Wednesday, January 8th. Leede Financial set a C$8.25 target price on Medexus Pharmaceuticals and gave the stock a “speculative buy” rating in a research note on Monday, September 30th. Finally, Alliance Global Partners raised Medexus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, December 23rd. Two equities research analysts have rated the stock with a buy rating and four have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Strong Buy” and a consensus target price of C$5.58.

Medexus Pharmaceuticals Stock Performance

TSE MDP opened at C$4.33 on Tuesday. The firm has a market cap of C$106.21 million, a price-to-earnings ratio of 86.60 and a beta of 1.96. The firm has a 50 day simple moving average of C$2.92 and a 200-day simple moving average of C$2.60. Medexus Pharmaceuticals has a one year low of C$1.47 and a one year high of C$4.60.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.